Atamyo Therapeutics (@atamyotx) 's Twitter Profile
Atamyo Therapeutics

@atamyotx

Our mission: to bring a new generation of best-in-class gene therapies to patients suffering from neuromuscular diseases.

ID: 1450950143629430787

linkhttp://atamyo.com calendar_today20-10-2021 22:21:28

35 Tweet

218 Followers

241 Following

LGMD2E (@lgmd2e) 's Twitter Profile Photo

Oggi 30 settembre l'ottava GIORNATA MONDIALE dedicata alla distrofia muscolare dei cingoli - patologie neuromuscolari LGMD. GFB ONLUS è impegnata nell'azione di sensibilizzazione su questa malattia rara Seguiteci sui profili social per rimanere aggiornati sulla GIORNATA.

Oggi 30 settembre l'ottava GIORNATA MONDIALE dedicata alla distrofia muscolare dei cingoli - patologie neuromuscolari LGMD. GFB ONLUS è impegnata nell'azione di sensibilizzazione su questa malattia rara Seguiteci sui profili social per rimanere aggiornati sulla GIORNATA.
GENETHON France (@genethonfr) 's Twitter Profile Photo

It's #LGMD Awareness Day! GENETHON France , Isabelle Richard and her team have been working on LGMDs for over 30 years. One #GeneTherapy product is currently in trial for #FKRP LGMD. A trial conducted by Atamyo Therapeutics , a Genethon spin-off 👉bit.ly/3Cmjk3W

It's #LGMD Awareness Day! <a href="/GenethonFr/">GENETHON France</a> , Isabelle Richard and her team have been working on LGMDs for over 30 years. One #GeneTherapy product is currently in trial for #FKRP LGMD. A trial conducted by <a href="/AtamyoTX/">Atamyo Therapeutics</a> , a Genethon spin-off

👉bit.ly/3Cmjk3W
Atamyo Therapeutics (@atamyotx) 's Twitter Profile Photo

It's #LGMD Awareness Day! Atamyo Therapeutics Isabelle Richard and her team have been working on LGMDs for over 30 years. One #GeneTherapy product is currently in trial for #FKRP LGMD. A trial conducted by Atamyo Therapeutics. Proud to develop treatments for this devastating disease

Atamyo Therapeutics (@atamyotx) 's Twitter Profile Photo

@atamyotx will be at #MeetingontheMed in Barcelona to present a company overview. Atamyo’s most advanced programs address different forms of #LGMD, with a clinical-stage program targeting LGMD-R9.#CellandGene #CGMed23

@atamyotx will be at #MeetingontheMed in Barcelona to present a company overview.  Atamyo’s most advanced programs address different forms of #LGMD, with a clinical-stage program targeting LGMD-R9.#CellandGene #CGMed23
Atamyo Therapeutics (@atamyotx) 's Twitter Profile Photo

Atamyo Therapeutics announces appointment of Roger Hajjar, MD, Dir of the Gene and Cell Therapy Institute of Mass General Brigham to it’s Board of Directors. Dr. Hajjar is a gene therapy pioneer and internationally recognized scientist. atamyotx.com #genetherapy #LGMD

<a href="/atamyotx/">Atamyo Therapeutics</a> announces appointment of Roger Hajjar, MD, Dir of the Gene and Cell Therapy Institute of <a href="/MassGenBrigham/">Mass General Brigham</a> to it’s Board of Directors. Dr. Hajjar is a gene therapy pioneer and internationally recognized scientist. atamyotx.com  #genetherapy #LGMD
Atamyo Therapeutics (@atamyotx) 's Twitter Profile Photo

Atamyo Therapeutics announces U.S. FDA cleared its IND for ATA-100  to proceed in a Phase 1b/2b #ClinicalTrials. ATA-100 is one-time #genetherapy for treatment of fukutin-related protein (FKRB) #LGMD Type 2I/R9. #musculardystrophy  Details: bit.ly/48fON5U

<a href="/AtamyoTX/">Atamyo Therapeutics</a> announces <a href="/US_FDA/">U.S. FDA</a> cleared its IND for ATA-100  to proceed in a Phase 1b/2b #ClinicalTrials. ATA-100 is one-time #genetherapy for treatment of fukutin-related protein (FKRB) #LGMD Type 2I/R9. #musculardystrophy  Details: bit.ly/48fON5U
Atamyo Therapeutics (@atamyotx) 's Twitter Profile Photo

Another key milestone reached for Atamyo Therapeutics and for the #LGMD community, this time with a potential one-time treatment for the devastating LGMD2C/R5 disease. #genetherapy #musculardystrophy

Another key milestone reached for <a href="/AtamyoTX/">Atamyo Therapeutics</a>  and for the #LGMD community, this time with a potential one-time treatment for the devastating LGMD2C/R5 disease. #genetherapy #musculardystrophy
Atamyo Therapeutics (@atamyotx) 's Twitter Profile Photo

@AtamyTX and our #LGMD #genetherapy programs will be represented at October conferences across the US and in EU. See you there. #musculardystrophy Details: bit.ly/468yBSx

@AtamyTX and our #LGMD #genetherapy programs will be represented at October conferences across the US and in EU. See you there. #musculardystrophy
Details: bit.ly/468yBSx
Atamyo Therapeutics (@atamyotx) 's Twitter Profile Photo

Atamyo Therapeutics stands by the #LGMD Community and reiterates its full commitment to develop treatments for LGMD and to better describe how this disease affects patients' lives. #LgmdAwareness #genetherapy

<a href="/AtamyoTX/">Atamyo Therapeutics</a> stands by the #LGMD Community and reiterates its full commitment to develop treatments for LGMD and to better describe how this disease affects patients' lives. #LgmdAwareness #genetherapy
Atamyo Therapeutics (@atamyotx) 's Twitter Profile Photo

First results of ATA-100 in Ph1b/2b clinical trial presented at #ESGCT23. ATA-100 is one-time #genetherapy for FKRP LGMD2I/R9. Also announced, DSMB authorized enrollment of 2nd dose cohort of the ATA-001 #clinicaltrials #LGMB #musculardystrophy bit.ly/46OqhYc

First results of ATA-100 in Ph1b/2b clinical trial presented at #ESGCT23. ATA-100 is one-time #genetherapy for FKRP LGMD2I/R9. Also announced, DSMB authorized enrollment of 2nd dose cohort of the ATA-001 #clinicaltrials #LGMB #musculardystrophy
bit.ly/46OqhYc
Atamyo Therapeutics (@atamyotx) 's Twitter Profile Photo

Atamyo Therapeutics' CEO, Stephane Degove, will present Atamyo's progress at the forthcoming 17th Annual European Life Sciences CEO Forum (#Sachs_ELSF) in Zurich, on 28th February at 12:20 (Room Berne). Looking forward to meeting the Finance and Biotech/Pharma community.

Atamyo Therapeutics (@atamyotx) 's Twitter Profile Photo

Atamyo Therapeutics Obtains Regulatory Authorization in Europe to Initiate a Clinical Trial for ATA-200, its Gene Therapy to Treat Limb-Girdle Muscular Dystrophy Type 2C/R5 - businesswire.com/news/home/2024…

Atamyo Therapeutics (@atamyotx) 's Twitter Profile Photo

Atamyo Therapeutics approved to initiate #clinicaltrial of ATA-200 in France and Italy. ATA-200 single-injection #genetherapy aimed to treat LGMD2C/R5 caused by mutations in the g-sarcoglycan gene. Ph1b study to evaluate safety and efficacy in children. bit.ly/3U440SB #LGMD

<a href="/AtamyoTX/">Atamyo Therapeutics</a> approved to initiate #clinicaltrial of ATA-200 in France and Italy. ATA-200 single-injection #genetherapy aimed to treat LGMD2C/R5 caused by mutations in the g-sarcoglycan gene. Ph1b study to evaluate safety and efficacy in children. bit.ly/3U440SB
#LGMD
CGTLive® (@cgt_live) 's Twitter Profile Photo

ICYMI: The trial, which will take the form of a dose escalation study, is expected to enroll 6 participants in total. #MuscularDystrophy #genetherapy #LimbGirdleMuscularDystrophy Atamyo Therapeutics Read more: cgtlive.com/view/atamyo-li…

Atamyo Therapeutics (@atamyotx) 's Twitter Profile Photo

Atamyo Therapeutics Obtains US FDA Fast Track Designation  for ATA-100, a Gene Therapy in Phase 1/2 Clinical Trials for Limb-Girdle Muscular Dystrophy Type R9 (LGMD-R9) atamyo.com/press-releases…

Atamyo Therapeutics (@atamyotx) 's Twitter Profile Photo

Atamyo Therapeutics is proud to announce this new partnership with The Dion Foundation to expand our first-in-human trial of ATA-200 #genetherapy to treat LGMD2C/R5 in the US. Read full press release here: bit.ly/3ZdZmEi #LGMD #MuscularDystrophy

<a href="/AtamyoTX/">Atamyo Therapeutics</a> is proud to announce this new partnership with The Dion Foundation to expand our first-in-human trial of ATA-200 #genetherapy to treat LGMD2C/R5 in the US. Read full press release here: bit.ly/3ZdZmEi  #LGMD #MuscularDystrophy
Atamyo Therapeutics (@atamyotx) 's Twitter Profile Photo

In honor of LGMD Awareness day, @atamyoTX announces key milestones in our #genetherapy for #LGMD. Read the full release: bit.ly/3Y2NZy3

In honor of LGMD Awareness day, @atamyoTX announces key milestones in our #genetherapy for #LGMD.  Read the full release: bit.ly/3Y2NZy3